Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's the role of sapropterin in modulating therapy?How can keytruda's side effects be managed during breast cancer therapy?Can azathioprine cause liver damage?Were any tests done to track sapropterin's impact?Can i eat oranges without affecting lipitor's effectiveness?
See the DrugPatentWatch profile for Ivosidenib
What is Ivosidenib and how does it treat AML? Ivosidenib is a targeted cancer therapy used to treat certain types of acute myeloid leukemia (AML) in adults [1]. It works by blocking the enzyme IDH1, which is often mutated in AML cells and helps them grow and divide uncontrollably. By inhibiting IDH1, ivosidenib slows down the growth and spread of cancer cells. How does ivosidenib target IDH1 in AML? Ivosidenib specifically targets the IDH1 mutant enzyme, which is present in about 20-30% of AML cases. The IDH1 mutation is a genetic change that leads to the production of an abnormal enzyme, which in turn causes the accumulation of a toxic metabolite called 2-hydroxyglutarate (2-HG). This metabolite disrupts normal cellular processes and promotes cancer cell growth. Ivosidenib binds to the IDH1 mutant enzyme, preventing it from functioning properly and thereby reducing the levels of 2-HG. What benefits has ivosidenib shown in treating AML patients? Clinical trials have demonstrated that ivosidenib can induce significant responses in patients with IDH1-mutant AML, achieving complete remission or durable disease control in some cases [2]. Ivosidenib has been shown to improve overall survival and increase the time to disease progression compared to traditional chemotherapy. What are the possible side effects of ivosidenib treatment? As with any cancer treatment, ivosidenib can cause side effects, including: * Diarrhea * Nausea and vomiting * Fatigue * Muscle and joint pain * Increased risk of QT prolongation (a heart condition) Patients should discuss any concerns or side effects with their healthcare provider. What are the patent and pricing details for ivosidenib? Ivosidenib is a branded medication developed by Agios Pharmaceuticals and approved by the FDA in 2018 [3]. According to DrugPatentWatch.com [3], the patent for ivosidenib expires in 2034. The cost of ivosidenib is around $10,000 per month, but this may vary depending on insurance coverage and individual circumstances. References [1] Ivosidenib | NCCN.org (nccn.org) [2] Ivosidenib in Patients with IDH1-Mutant Advanced Relapsed or Refractory Acute Myeloid Leukemia | NEJM (nejm.org) [3] DrugPatentWatch.com (drugpatentwatch.com)